Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cesar Garcia

Physician Assistant Pharr, TX Physician Assistant

NPI 1912534819 CMS profile 11252531

801 W Kiwi Ave, Pharr, TX 78577

Open in the dashboard

General payments

$8,907

193 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cesar Garcia of Pharr, TX is reported in the CMS Open Payments database as having received $8,907 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $801 37
2024 General $1,224 68
2023 General $5,291 59
2022 General $1,569 28
2021 General $22 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cesar Garcia
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Cesar Garcia were reported at $801. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Cesar Garcia Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $22 $132 $37–$438 $132
2022 $1,569 $155 $48–$522 $149
2023 $5,291 $167 $52–$557 $160
2024 $1,224 $178 $55–$600 $164
2025 $801 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $4,748 40 payments
  2. OptiNose US, Inc. $1,470 34 payments
  3. Novo Nordisk Inc $526 28 payments
  4. AstraZeneca Pharmaceuticals LP $331 13 payments
  5. Amgen Inc. $318 16 payments
  6. Inspire Medical Systems, Inc. $300 5 payments
  7. Regeneron Healthcare Solutions, Inc. $169 7 payments
  8. AbbVie, Inc. $159 8 payments
  9. Lilly USA, LLC $144 14 payments
  10. Stryker Corporation $132 2 payments
  11. Other $608 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,215 175 payments
  2. Travel and Lodging $3,530 13 payments
  3. Education $161 5 payments
Products named General payments · program years 2021–2025
  1. PROPEL $2,560 22 payments
  2. NUVENT $2,053 15 payments
  3. Xhance $1,470 34 payments
  4. INSPIRE $300 5 payments
  5. Ozempic $266 16 payments
  6. AIRSUPRA $241 8 payments
  7. FARXIGA $215 7 payments
  8. RYBELSUS $205 13 payments
  9. Otezla $169 13 payments
  10. DUPIXENT $169 7 payments
  11. Other $1,998 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

1,653

Median for Physician Assistant: 241

Drug cost

$118,363

Median for Physician Assistant: $4,110

Branded share of claims

17.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 40 $40,047
Ozempic Semaglutide Brand 11 $13,397
Mounjaro Tirzepatide Brand 13 $13,317
Jardiance Empagliflozin Brand 12 $13,021
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 11 $10,654
Myrbetriq Mirabegron Brand 19 $8,786
Lagevrio (Eua) Molnupiravir Brand 16 $6,350
Albuterol Sulfate Hfa Albuterol Sulfate Brand 33 $880
Atorvastatin Calcium Generic 68 $703
Ipratropium Bromide Generic 22 $565

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xhance
  • OptiNose US, Inc. $165
$165 — —
VRAYLAR
  • AbbVie, Inc. $153
$153 — —
EVENITY
  • Amgen Inc. $125
$125 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $102
$102 — —
RYBELSUS
  • Novo Nordisk Inc $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record